摘要
目的探讨人附睾蛋白4(HE4)和糖类抗原125(CA125)联合检测在卵巢癌诊断中的应用价值。方法对比分析卵巢癌患者、卵巢良性肿瘤患者和健康对照组间的血清HE4和CA125表达差异;并将卵巢癌患者按FIGO分四期,对各期的检测结果进行对比分析。结果 (1)卵巢癌患者组HE4和CA125浓度明显高于卵巢良性肿瘤患者组和健康对照组(P<0.01)。(2)HE4和CA125联合检测对卵巢癌诊断的敏感度为90.2%,特异度为85.5%。(3)FIGO分期与HE4水平呈正相关(P<0.05),FIGO分期与CA125水平无明显相关性(P>0.05)。结论 HE4和CA125联合检测能提高卵巢癌诊断的敏感性对卵巢癌早期诊断,而且对卵巢良恶性肿瘤的鉴别诊断及判断卵巢癌预后具有重要意义。
Objective To discuss the application value of human epididymis secretory protein 4 （HFA） and CA125 in diagnosis of ovarian carcinoma. Methods The HE4 and CA125 levels in the serum specimens of ovarian carcinoma group, benign ovarian diseases and healthy women group were detected by enzyme - linked immunosorbent assay （ELISA） and chemiluminescent microparticle ,y, respectively. Then the expression difference of HE4 and CA125 among the three groups and ovarian carcinoma patients at different stages were compared and analyzed. Results 1. The levels of HE4 and CA125 were significantly higher in ovarian group than those of the benign ovarian diseases group and healthy women group （P 〈 0. 01 ）. 2. The sensitivity of joint detection of HE4 and CA125 was 90.2% , and the diagnostic specificity was 85.5%. 3. FIGO stage and HELl levels were positively correlated （P 〈 0.05 ）, while FIGO stage and CA125 levels had no significant correlation （P 〉 0.05 ）. Conclusion In addition to high sensitivity for early diagnosis of ovarian carcinoma, the combined detection of serum HE4 and CA125 also have significant clinical value in the differential diagnosis of magnificent ovarian tumors and judgment of clinical prognosis.
出处
《中国卫生检验杂志》
北大核心
2013年第17期3370-3373,共4页
Chinese Journal of Health Laboratory Technology
关键词
人附睾蛋白4
糖类抗原125
卵巢癌
FIGO分期
Human epididymis secretory protein 4
Carbohydrate antigen 125
Ovarian carcinoma
FIGO stage
